Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 44Recruiting 32Not yet recruiting 4Terminated 2Completed 2Suspended 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1CNS 1Breast 1

Conditions

Urologic Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Soft Tissue Neoplasms 1Sarcoma 1Recurrence 1Pharyngeal Neoplasms 1Neurofibromatosis 2 1Neoplasms, Mesothelial 1Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Lymphangioleiomyomatosis 1Lung Neoplasms 1Erdheim-Chester Disease 1Endocrine Gland Neoplasms 1Castleman Disease 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 28Carboplatin 18Cisplatin 15Nivolumab 13Pemetrexed 12Paclitaxel 11Specimen Handling 10Ipilimumab 10Gemcitabine 10venetoclax 8durvalumab 8atezolizumab 8Radiotherapy 8Radiosurgery 8Magnetic Resonance Spectroscopy 8Docetaxel 7Cyclophosphamide 7Biopsy 7fludarabine 6enzalutamide 6Bevacizumab 6tislelizumab 5tazemetostat 5X-Rays 5Trastuzumab 5Surveys and Questionnaires 5Practice Guidelines as Topic 5Interviews as Topic 5Injections 5Dexamethasone 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Disulfides × 90 days × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT04902040 2026-04-30

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

M.D. Anderson Cancer Center

Phase 1/2 Terminated
19 enrolled 11 charts
GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡